Latus Pharma ApS: Financial statements 2024
CVR: 36974214
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
Latus Pharma ApS (CVR 36974214) has filed annual accounts for 2024. In 2024, the company reported revenue of DKK -6,897 and a net result of DKK -6,897 compared with DKK -10,814 the year before. Equity in the 2024 report amounted to DKK 88,483. The solvency ratio was 100%.
- Revenue
- DKK -6,897
- Gross Profit
- DKK -6,897
- Profit/Loss
- DKK -6,897
- Equity
- DKK 88,483
- Total Assets
- DKK 88,483
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | -7 t. | -7 t. | -7 t. | 88 t. | - |
| 2023 | 0 | -11 t. | -11 t. | 94 t. | - |
| 2022 | 0 | -14 t. | -14 t. | 105 t. | - |
| 2021 | 0 | -4 t. | -4 t. | 119 t. | - |
| 2020 | 0 | -4 t. | -4 t. | 123 t. | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
Latus Pharma ApS has published its annual report for 2023. Revenue came to DKK 0, and the net result was DKK -10,814.
About Latus Pharma ApS
Latus Pharma ApS is a Danish company of the type Anpartsselskab based in Køge, founded in 2015. The company is registered under the industry Andre liberale, videnskabelige og tekniske tjenesteydelser i.a.n.. The management consists of Jørgen Wittendorff. The company is owned by Jørgen Wittendorff. In 2025, the company reported revenue of DKK -6,991 and a net result of DKK -6,991 compared with DKK -6,897 the year before. Equity in the 2025 report amounted to DKK 82,569.